HC Wainwright Has Optimistic Outlook of COCP FY2024 Earnings

Cocrystal Pharma, Inc. (NASDAQ:COCP) – HC Wainwright boosted their FY2024 earnings per share estimates for Cocrystal Pharma in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($1.87) per share for the year, up from their previous estimate of ($2.03). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($1.91) per share. HC Wainwright also issued estimates for Cocrystal Pharma’s Q4 2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.54) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.50) EPS.

Cocrystal Pharma Price Performance

Shares of NASDAQ COCP opened at $2.09 on Friday. The stock’s fifty day moving average price is $2.16 and its two-hundred day moving average price is $1.98. The firm has a market cap of $21.26 million, a price-to-earnings ratio of -1.13 and a beta of 1.53. Cocrystal Pharma has a one year low of $1.33 and a one year high of $3.26.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.